Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
December 1, 2015
Assignees:
The United States of America, as represented by the Secretary, Dept. of Health and Human Services, GlobeImmune, Inc.
Inventors:
Claudia Palena, Zhimin Guo, David Apelian, Jeffrey Schlom
Abstract: In this application is described a composition and method for inducing in a subject anti-hapten antibodies without inducing antibodies to the carrier protein. Kits for designing and making compositions with desired haptens are also described.
Type:
Grant
Filed:
February 8, 2013
Date of Patent:
November 24, 2015
Assignees:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT OF HEALTH HUMAN SERVICES
Inventors:
Carl R. Alving, Gary R. Matyas, Arthur E. Jacobson, Fuying Li, Malliga R. Iyer, Kenner C. Rice, Kejun Cheng, Alexander Mayorov
Abstract: The invention provides a method for detecting the presence or absence of a biomarker in a biological sample at a very low concentration comprising the steps of (a) contacting the biological sample with a capture binding sequence immobilized on a surface, (b) providing a conjugate comprising a detection binding sequence-glucose oxidase, (c) contacting the surface with the detection binding sequence-glucose oxidase conjugate, (d) separating any unbound detection binding sequence-glucose oxidase conjugate from the surface, (e) incubating the resulting surface with a glucose solution and a mixture comprising gold nanoparticles and a gold salt, wherein the gold nanoparticles have an initial particle size of about 5 nm, and (f) observing any change in color of the mixture. The invention also provides a method for diagnosing the presence of a prostate cancer biomarker in a subject and a kit for detecting or quantifying a biomarker in a biological sample.
Type:
Application
Filed:
May 18, 2015
Publication date:
November 19, 2015
Applicant:
The United States of America, as represented by the Secretary, Dept. of Health and Human Services
Abstract: The present description relates to an inhibitory RNA molecule, comprising an oligonucleotide that selectively knocks down expression of either Nanog or a Nanog pseudogene, a vector capable of encoding such inhibitory RNA molecule, pharmaceutical compositions comprising said vector, and methods of treating cancer by administration of said pharmaceutical composition.
Type:
Grant
Filed:
December 6, 2011
Date of Patent:
October 20, 2015
Assignee:
The United States of America, as represented by the Secretary, Dept. of Health and Human Services
Abstract: The invention provides an isolated or purified CD8+? T cell which comprises an antigen-specific T cell receptor and an exogenous nucleic acid encoding a microRNA-155 (miR-155) molecule, and methods of preparing the same. The invention also provides a pharmaceutical composition comprising the CD8+ T cell a carrier. Further provided is a method for treating or preventing a medical condition, such as cancer, by adoptively transferring to a mammal an amount of the CD8+? T cells effective to treat or prevent the medical condition.
Type:
Application
Filed:
October 17, 2013
Publication date:
October 1, 2015
Applicant:
The United States of America, as represented by the Secretary, Dept. of Health and Human Service
Inventors:
Yun Ji, Nicholas P. Restifo, Luca Gattinoni
Abstract: It is disclosed herein that expression of microRNA-26 is decreased in hepatocellular (HCC) tumor tissue relative to non-cancerous tissue, and that a low level of microRNA-26 is associated with a poor clinical outcome. It is also disclosed herein that a low expression level of microRNA-26 is correlated with a favorable response to interferon (IFN)-? therapy in HCC patients. Thus, provided herein is a method of predicting the clinical outcome of a patient diagnosed with HCC comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. Also provided is a method of selecting a patient diagnosed with HCC as a candidate for IFN-? therapy, comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. A method of identifying therapeutic agents for the treatment of HCC, comprising screening candidate agents in vitro to select an agent that increases expression of microRNA-26 in HCC cells are also provided.
Type:
Grant
Filed:
June 11, 2009
Date of Patent:
September 8, 2015
Assignees:
The Ohio State University, Fudan University, The United States of America as Represented by the Secretary of the Dept. of Health and Human Services
Inventors:
Xin W. Wang, Junfang Ji, Carlo M. Croce, Hui-chuan Sun, Zhao-you Tang
Abstract: Antibodies and antibody fragments that bind to insulin-like growth factor (IGF) 1 receptor (IGF-1R) or IGF-2, as well as methods of using the antibodies for inhibiting the IGF-mediated signaling pathway, inhibiting IGF-1R signaling, and treating cancer, are described. A method of detecting the presence of IGF-1R or IGF-2 in a sample using the disclosed antibodies and antibody fragments is also described.
Type:
Application
Filed:
May 13, 2015
Publication date:
September 3, 2015
Applicant:
The United States of America, as represented by the Secretary, Dept. of Health & Human Services
Abstract: The present invention provides a vaccine and method for making same which is effective to elicit a desired antibody against a target antigen comprising a primary immunogen and a secondary immunogen, wherein the primary immunogen is effective to elicit B cell receptors (BCRs) that are on the maturational pathway of the desired antibody and have an intermediate degree of somatic mutational diversity, and the secondary immunogen comprises an epitope of the desired target antibody and is effective to further diversify the BCRs sufficient to form mature BCRs having the identical or substantially identical sequence as the desired antibody.
Type:
Application
Filed:
January 20, 2015
Publication date:
July 23, 2015
Applicant:
The United States of America, as represented by the Secretary, Dept. of Health & Human Services
Abstract: Provided are methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. The interaction between DR3 and TL1A can be blocked by reducing expression of TL1A. The interaction between DR3 and TL1A can be blocked by administration of anti-DR3 antibodies. The interaction between DR3 and TL1A can be blocked by administration of anti-TL1A antibodies. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease (IBD).
Type:
Grant
Filed:
March 13, 2012
Date of Patent:
June 30, 2015
Assignee:
The United States of America, as represented by the Secretary, Dept. of Health and Human Services
Inventors:
Richard M Siegel, Francoise Meylan, Yun-Jeong Song
Abstract: The present invention provides variant VEGF polypeptides which have been altered in their C-terminal heparin binding region to lower their heparin binding affinity. These variants have been found to act as receptor antagonists for VEGF receptors and antagonize angiogenesis. These variants are useful to treat diseases characterized by pathological angiogenesis.
Type:
Application
Filed:
April 26, 2013
Publication date:
May 7, 2015
Applicant:
The United States of America, as represented by the Secretary, Dept. of Health & Human Services
Abstract: Disclosed herein are methods for detecting, diagnosing and/or prognosing a malignant adrenocortical tumor. Also disclosed are methods of treating a malignant adrenocortical tumor, such as ACC. In some examples, the method of diagnosing and/or prognosing includes obtaining a sample comprising genomic DNA from a subject at risk of acquiring or suspected to have an adrenocortical tumor; isolating genomic DNA from the sample; and measuring the level of one or more methylated genomic CpG dinucleotide sequences in one or more of the adrenocortical genomic targets in the sample, wherein an increase in the level of methylation of the one or more genomic CpG dinucleotide sequences in the sample compared to a control indicates a malignant adrenocortical tumor.
Type:
Application
Filed:
March 12, 2013
Publication date:
April 30, 2015
Applicant:
The United States of America, as Represented by the Secretary, Dept. of Health & Human Services
Inventors:
Electron Kebebew, Nesrin S. Rechache, Paul S. Meltzer, Yong-hong Wang
Abstract: Described herein is the finding that hyaluronan antagonists that inhibit hyaluronan signaling are capable of inhibiting airway inflammation and airway hyperresponsiveness (AHR). The present disclosure provides a method of preventing or reducing AHR in a subject suffering from or at risk for AHR by administering a hyaluronan antagonist. Also provided is a method of treating an airway disease or disorder in a subject by administering a hyaluronan antagonist. Hyaluronan antagonists include, for example, heparosan and hyaluronan oligosaccharides (oHAs). In some embodiments, the hyaluronan antagonist is administered locally to the airway, such as with an inhaler or nebulizer.
Type:
Application
Filed:
March 8, 2013
Publication date:
April 16, 2015
Applicants:
The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Duke University, MUSC Foundation for Research Development, The Universtiy of North Carolina at Chapel Hill
Inventors:
Stavros Garantziotis, John W. Hollingsworth, Bryan P. Toole, Jian Liu
Abstract: A system and method for preprocessing magnetic resonance spectroscopy (MRS) data of brain tissue for pattern-based diagnostics is disclosed. The MRS preprocessing system includes an MRS preprocessing module that executes an operation that normalizes MRS spectrum data, recalibrates and scales the normalized MRS spectrum data, and then renormalizes the scaled MRS spectrum data. The resulting preprocessed MRS data is used to assist in identifying abnormalities in tissues shown in MRS scans.
Type:
Application
Filed:
September 5, 2014
Publication date:
March 5, 2015
Applicant:
The United States of America, as represented by the Secretary, Dept. of Health and Human Services
Inventors:
Jon G. Wilkes, Dan A. Buzatu, Pierre Alusta, Bruce Pearce, Ryan M. Kretzer, Inessa IM, Richard D. Beger
Abstract: The invention provides systems, methods, and instrumentation for aiding the performance of an image guided procedure of the anatomy of a patient such as, for example, the prostate. The invention includes a plurality of lumens therein and a balloon portion or other fixating portion. In some embodiments, the catheter includes a lumen for introducing a contrast agent visible to an imaging modality external to the anatomy of the patient. Image space data of the catheter within the anatomy of the patient may be obtained using the imaging modality. The catheter also includes at least a lumen for inserting a registration device for obtaining patient space data regarding the anatomy of the patient. Other lumens and/or other elements visible to the imaging modality may be used. The image space data may be registered to the patient space data for use during an image guided procedure to the anatomy of the patient.
Type:
Grant
Filed:
March 30, 2007
Date of Patent:
February 3, 2015
Assignees:
Koninklijke Philips N.V., The United States of America as represented by the Secretary, Dept. of Health and Human Services
Inventors:
Neil David Glossop, Bradford Johns Wood
Abstract: The invention provides a method of treating or preventing viral diseases in a mammal comprising administering to the mammal an interleukin (IL)-21 blocking agent in an amount effective to treat or prevent the viral disease in the mammal. Also provided is a method of reducing the activation or recruitment of immune cells in a mammal comprising administering to the mammal an IL-21 blocking agent in an amount effective to reduce the activation or recruitment of immune cells in the mammal. Methods of decreasing the expression of at least one cytokine or at least one protein in a mammal comprising administering to the mammal an IL-21 blocking agent in an amount effective to decrease the expression of the cytokine or the protein are also provided.
Type:
Application
Filed:
December 21, 2012
Publication date:
January 29, 2015
Applicant:
The United States of America, as represented by the Secretary, Dept. of Health and Human Services
Abstract: The invention is directed to compositions capable of augmenting the immunogenicity of a vaccine. The composition, or adjuvant, is administered to a mammal in need thereof in sequential or concurrent combination with a vaccine antigen. In one preferred aspect, the adjuvant is provided in the form of a recombinant poxvirus vector, such as a vaccinia virus vector, which comprises a nucleic acid sequence encoding IL-15.
Type:
Application
Filed:
January 15, 2014
Publication date:
December 25, 2014
Applicant:
The United States of America, as represented by the Secretary, Dept. of Health & Human Services
Inventors:
Liyanage P. Perera, Thomas A. Waldmann, Sang-Kon Oh, Jay A. Berzofsky
Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
Type:
Application
Filed:
September 11, 2012
Publication date:
December 25, 2014
Applicant:
The United States of America, as represented by the Secretary, Dept. of Health and Human Services
Inventors:
Paul F. Robbins, Steven A. Rosenberg, Shiqui Zhu, Steven A. Feldman, Richard A. Morgan
Abstract: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.
Type:
Application
Filed:
May 22, 2014
Publication date:
November 13, 2014
Applicant:
The United States of America, as represented by the Secretary, Dept. of Health and Human Services
Inventors:
Rong-Fu Wang, Steven A. Rosenberg, Gang Zeng
Abstract: A computer-implemented method for determining magnetic field inversion time of a tissue species includes generating a T1-mapping image of a tissue of interest, the T1-mapping image comprising a plurality of T1 values within an expected range of T1 values for the tissue of interest. An image mask is created based on predetermined identification information about the tissue of interest. Next, an updated image mask is created based on a largest connected region in the image mask. The updated image mask is applied to the T1-mapping image to yield a masked image. Then, a mean relaxation time value is determined for the largest connected region. The mean relaxation time value is then used to determine a time point for nulling longitudinal magnetization.
Type:
Application
Filed:
April 4, 2014
Publication date:
October 23, 2014
Applicant:
The United States of America, as represented by the Secretary, Dept of Health and Human Services
Inventors:
Bruce S. Spottiswoode, Xiaoguang Lu, Xiaoming Bi, Hui Xue, Christopher Glielmi, Peter Kellman, Andreas Greiser
Abstract: The instant invention is directed towards tetracycline compositions, and methods of inhibiting Tdp1 activity, and methods of treating Tdp1-associated disorders.
Type:
Grant
Filed:
September 29, 2008
Date of Patent:
October 21, 2014
Assignee:
The United States of America, as Represented by the Secretary, Dept. of Health and Human Services